FINAL
Careers Alternatives for Scientists
Science & Business Club
November 13, 2014
Michael Fath, PhD
Senior Director, Global Marketing Bioscience
Grifols, Inc.
Topics for Today
•
•
Introduction
Harvard Paths
http://www.hms.harvard.edu/dms/resources/paths.html
–
–
–
–
–
–
•
•
•
•
•
Biotechnology
Consulting
Law
Education
Policy & Non-profit
Science writing
McKinsey
Additional Consulting Firms
Preparing for the Interview
Some final words of advice
Q&A
2
2
Who am I?
•
Grifols Inc. Senior Director, Global Marketing Bioscience – Pulmonology & Thrombolysis
–
–
–
–
•
Global marketing for Prolastin and Prolastin-C (alpha-1 antitrypsin replacement therapy)
Launch of the AlphaKit QuickScreen (point-of-care screen that detects the Z-allele of alpha-1 antitrypsin)
Commercial development of aerosol alpha-1 for cystic fibrosis and diabetes
Commercial development of Pulmaquin - liposomal encapsulated ciprofloxacin in Phase III for bronchiectasis
Abbott Laboratories, Abbott Park, IL
–
2010 -
1998-2009
Multiple management positions including US Brand Marketing, Medical Affairs, Strategic Planning, Business
Development, and New Product Planning.
•
Management consultant with McKinsey & Co. in Chicago
•
Post-doctoral fellowship in Molecular Genetics at the University of Chicago
•
PhD in Microbiology and Molecular Genetics from the Harvard Medical School - studied the
biosynthesis and secretion of peptide antibiotics.
The material in this presentation is mine and
3
does not necessarily reflect the views of Grifols
3
2005-2008
What does Grifols do?
•
Global healthcare company with >13,000
employees
•
Recent growth driven by two major
acquisitions:
•
•
Talecris Biotherapeutics – 6/2011
•
Novartis Diagnostics – 11/2013
The new Grifols
4
•
World’s highest plasma fractionation capacity
•
World leading sales of IVIG and A1PI
•
The largest number of source plasma
collection centers in the US
•
Subsidiaries in >24 countries and sales in
more than 90 countries
Grifols’ Global Headquarters in Barcelona
Grifols SA, Barcelona
NASDAQ: GRFS
4
4
Vertically Integrated Business Model
Plasma –Derived Therapies
Donation
Testing
Inventory
Production
• Geographic diversity to ensure uninterrupted supply for production
• Quality control and maximum oversight across all functions
5
5
Three Grifols divisions develop, produce
and distribute healthcare products
worldwide
Bioscience
Plasma-derived therapies
Diagnostic
In vitro diagnostics, analyzers &
reagents
6
6
Hospital
Hospital logistics, IV solutions,
medical devices
Grifols Financial History
7Source: http://www.grifols.com/documents/10180/180220/2h13-en.pdf/f107b115-e25e-42e9-8b4b-8a69c96aac65
7
Grifols Product Portfolio
Immunology
Pulmonology
Hematology
Grifols Albumin Products
8
8
8
Why discuss Grifols?
• If you are interested in a career outside of
academia, you want to start thinking about
science as a business.
• What are the economics of biotech,
pharma, medical devices?
• How do your skills help you in these
industries?
9
9
Top Companies and Drugs
10
10
Table 1. Top 100 Drugs by Sales
Rank
Drug (brand name)
Sales, 2013
1
Abilify
$6,460,215,394
2
Nexium
$6,135,667,614
3
Humira
$5,549,996,855
4
Crestor
$5,310,818,889
5
Cymbalta
$5,219,860,418
6
Advair Diskus
$5,121,312,668
7
Enbrel
$4,681,201,645
8
Remicade
$4,098,233,242
9
Copaxone
$3,697,182,238
10
Neulasta
$3,580,364,758
11
Rituxan
$3,288,614,045
12
Lantus Solostar
$3,005,681,663
13
Spiriva Handihaler
$2,998,207,542
14
Atripla
$2,856,818,557
15
Januvia
$2,843,496,907
16
Avastin
$2,688,414,938
17
Lantus
$2,556,825,619
18
Oxycontin
$2,534,909,675
19
Lyrica
$2,415,254,835
20
Epogen
$2,280,696,834
21
Celebrex
$2,237,658,764
22
Truvada
$2,235,712,145
23
Diovan
$2,169,819,482
24
Herceptin
$1,938,804,857
25
Gleevec
$1,896,982,614
Harvard Paths
• www.hms.harvard.
edu/dms/resource
s/paths.html
–
–
–
–
–
Biotechnology
Consulting
Law
Education
Policy & Nonprofit
– Science writing
11
11
McKinsey: recruiting process for full-time
and internship opportunities
12Source: jennifer_gerhard@mckinsey.com
12
McKinsey Seminars
13Source: jennifer_gerhard@mckinsey.com
13
McKinsey Rotations and
Internships
14Source: jennifer_gerhard@mckinsey.com
14
McKinsey Fellowship and Full-time
Positions
15Source: jennifer_gerhard@mckinsey.com
15
IMS Consulting
16Source: IMS Consulting
16
Inventiv
17Source: Inventiv website
17
Campbell Alliance
18Source: Campbell Alliance 2008
18
Preparing for a Consulting
Interview
• The Case Interview
• Understand the company
• Understand the industry
19
19
Some Resources
20
20
Case in Point Highlights
• Interviewers don't ask case questions to embarrass and
humiliate you. They don't ask case questions to see you
sweat and squirm (although some might consider it a
side perk). They do ask case questions ...
– to probe your intellectual curiosity
– to test your analytical ability
– to test your ability to think logically and organize your answer * to
observe your thought process
– to probe your tolerance for ambiguity and data overload * to
assess your poise, self-confidence, and communication skills
under pressure
– to discover your personality
– to see whether you're genuinely intrigued by problem-solving
– to determine whether consulting is a good fit for you
http://files.2epub.net/sites/default/files/eb_converted/2013_11/case_in_point_8th_edition.pdf
21
21
The Case Commandments
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
Listen to the Question.
Take Notes.
Summarize the Question.
Verify the Objectives.
Ask Clarifying Questions.
Organize Your Answer.
Hold That Thought for "One Alligator."
Manage Your Time.
Work the Numbers.
Be Coachable.
Be Creative and Brainstorm.
Exude Enthusiasm and a Positive Attitude.
Bring Closure and Summarize.
22
http://files.2epub.net/sites/default/files/eb_converted/2013_11/case_in_point_8th_edition.pdf
22
Some Final Observations
• There are many options for you
• Going through this self-evaluation process
can be useful regardless of your final path
• Take the time to:
– Build your talents thought practice
– Avoid The Shallows
– Be prepared
23
23
Questions?
• Thank you for your attention
• Contact me at michaelfath@yahoo.com if
you have additional questions.
24
24